ArticleFuture oncology (London, England)2025
PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unsatisfactory prognosis of patients with early-stage hepatocellular carcinoma (HCC) emphasizes the urgent need for perioperative treatment to reduce recurrence after surgery. The combination of transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and programmed cell death protein 1 (PD-1) inhibitor has emerged as a promising treatment for unresectable HCC, yet its perioperative application was not explored. PERI-START is a prospective, single arm phase II trial which aims to investigate the efficacy and safety of TACE, tislelizumab (PD-1 inhibitor), and lenvatinib (TKI) in perioperative (neoadjuvant and adjuvant) use for resectable, high-risk HCC. Within 1 week after enrollment, TACE will be administered. Subsequently, intravenous tislelizumab will be given every 3 weeks in combination with daily oral lenvatinib. Unless disease progression occurs, liver resection will then be performed. 4-6 weeks after liver resection, tislelizumab and lenvatinib will be resumed for 6 months. The primary endpoint is the major pathological response (MPR) rate, with secondary endpoints including objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), and adverse events (AEs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.